Stay updated on Acalabrutinib in Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Acalabrutinib in Ovarian Cancer Clinical Trial page.

Latest updates to the Acalabrutinib in Ovarian Cancer Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedA Locations section has been added with Arizona and Pennsylvania study sites (replacing the prior standalone Arizona Locations and Pennsylvania Locations blocks). The page revision is updated to v3.3.3, and the HHS Vulnerability Disclosure link has been removed.SummaryDifference0.4%

- Check22 days agoNo Change Detected
- Check37 days agoChange DetectedOnly a minor revision/version update is shown (Revision: v3.3.2) in the page footer; no core content or study details appear to have changed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check44 days agoChange DetectedThe page footer now shows Revision: v3.3.1 instead of Revision: v3.2.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check51 days agoChange DetectedAdded related topics: Ovarian cancer and MedlinePlus Genetics to the study page. Removed a banner about government funding status and NIH operations.SummaryDifference0.6%

- Check58 days agoChange DetectedThe MedlinePlus related topics section no longer lists 'Ovarian Cancer' and 'MedlinePlus Genetics'. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check65 days agoChange DetectedThe page underwent a visual/UI refresh with a new header and updated formatting; no core content such as study title, NCT number, eligibility criteria, or outcomes changed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

Stay in the know with updates to Acalabrutinib in Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Acalabrutinib in Ovarian Cancer Clinical Trial page.